Utility of Evaluating HCV in an Uninsured Population

Digestive Diseases and Sciences

Volumn 60, Issue 4, 2015, Pages 1092-1097

  Donepudi, Indira ^a   Paredes, Angelo ^a   Hubbard, Sarah ^a   Awad, Chadi ^a   Sterling, Richard K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hepatitis C virus; Indigent care; Uninsured

Indexed keywords

ANTIVIRUS AGENT;

ADULT; FEMALE; HEPATITIS C, CHRONIC; HUMAN; MALE; MEDICALLY UNINSURED; MEDICATION COMPLIANCE; MIDDLE AGED; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MEDICAL INDIGENCY; MEDICALLY UNINSURED; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84934272920     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3416-8     Document Type: Article

References (28)

1. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156:761–773.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
3. Louie KS, Laurent S, Forssen UM, et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012;12:86.
4. Ong JP, Collantes R, Pitts A, et al. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol. 2005;39:826–830.
5. Putka B, Mullen K, Birdi S, et al. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat. 2009;16:814–821.
6. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S135–S144.
7. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366:273–275.
8. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;31(364):1195–1206.
9. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
10. Bacon BR, Gordon SC, Lawitz E, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;23(364):1207–1217.
11. Stepanova M, Kanwal F, El-Serag HB, et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53:737–745.
12. Moirand R, Bilodeau M, Brissette S, et al. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol. 2007;21:355–361.
13. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57:1325–1332.
14. Fusfeld L, Aggarwal J, Dougher C, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13:234.
15. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
16. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
17. Smith BD, Morgan RL, Beckett GA. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817–822.
18. Lynn RB. Hepatitis C virus testing of persons born during 1945–1965. Ann Intern Med. 2013;158:704–705.
19. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.
20. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011;31:18–22.
21. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.
22. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–516.
23. Chen EY, Sclair SN, Czul F, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol. 2013;11:1014–1020.
24. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859.
25. Kanwal F, White DL, Tavakoli-Tabasi S. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014;12:327–333.
26. Surjadi M, Torruellas C, Ayala C, et al. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56:213–219.
27. Smith JO, Sterling RK. Systematic review: noninvasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009;30:557–576.
28. Bonder A, Afdhal N, et al. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16:372.